-
Mashup Score: 1
Medical oncologists review the FLAURA2 study looking at osimertinib with or without chemotherapy in EGFR-mutated NSCLC and discuss patients for whom they would consider the therapy.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology | Research To Practice - 5 day(s) ago
Register for this complimentary event with the “Register Now” button above, which will take you to our Zoom registration page. Join us on Wednesday, May 8 th for this CME/MOC-accredited webinar 5:00 PM – 6:00 PM ET Faculty Justin F Gainor, MD Director, Center for Thoracic Cancers Program Director of Targeted Immunotherapy in the Henri and Belinda Termeer Center for Targeted Therapies Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Karen Reckamp,
Source: m.researchtopractice.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 5Fox Chase Cancer Center Researchers Show Estrogen Metabolites Contribute to Development of Lung Cancer Among People Who Never Smoked - 5 day(s) ago
Fox Chase Cancer Center researchers showed that estrogen is metabolized in lungs, contributing to the development of lung cancer in never smokers.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 17
Lung cancer screening using low-dose computed tomography (LDCT) carefully implemented has been found to reduce deaths from lung cancer. Optimal management starts with selection of eligibility criteria, counseling of screenees, smoking cessation, selection of the regimen of screening which specifies the imaging protocol, and workup of LDCT findings. Coordination of clinical, radiologic, and interventional teams and ultimately treatment of diagnosed lung cancers under screening determine the benefit of LDCT screening.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 73
We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic non‒small-cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) <1% enrolled in phase 3 studies of pembrolizumab plus chemotherapy versus placebo plus chemotherapy.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 72
We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic non‒small-cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) <1% enrolled in phase 3 studies of pembrolizumab plus chemotherapy versus placebo plus chemotherapy.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Increasingly Targeted ADCs Drive NSCLC Treatment Innovations - 17 day(s) ago
Shirish M, Gadgeel, MD, highlights key treatment advances achieved with antibody-drug conjugates in non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Increasingly Targeted ADCs Drive NSCLC Treatment Innovations - 19 day(s) ago
Shirish M, Gadgeel, MD, highlights key treatment advances achieved with antibody-drug conjugates in non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2FDA Approves Alecensa for ALK-Positive NSCLC - 19 day(s) ago
The Food and Drug Administration approved Alecensa for patients with ALK-positive non-small cell lung cancer that was surgically removed.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 2Radiation, Durvalumab, and Chemo Improve Survival in ES-SCLC - 21 day(s) ago
Adding low-dose radiotherapy to standard-of-care durvalumab and chemotherapy led to survival benefits among patients with extensive-stage small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Medical oncologists review the FLAURA2 study looking at osimertinib with or without chemotherapy in EGFR-mutated NSCLC and discuss patients for whom they would consider the therapy. #lcsm | @JSabari https://t.co/la7quKdCMM